Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

BioLife Solns Q4 2023 Adj EPS $(0.210) Beats $(0.340) Estimate, Sales $32.732M Miss $33.399M Estimate

Author: Benzinga Newsdesk | February 29, 2024 05:06pm
BioLife Solns (NASDAQ:BLFS) reported quarterly losses of $(0.210) per share which beat the analyst consensus estimate of $(0.340) by 38.24 percent. The company reported quarterly sales of $32.732 million which missed the analyst consensus estimate of $33.399 million by 2.00 percent. This is a 26.04 percent decrease over sales of $44.259 million the same period last year.

Posted In: BLFS


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist